The main mechanism of action of GLP-1 analogs is to increase insulin production and decrease the production of glucagon, a hormone that raises blood sugar levels. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining ground as therapeutic modalities in combination with insulin in patients with type 2 diabetes mellitus. The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. Recently, 4 cardiovascular outcome trials with GLP-1RAs have been reported 4, 5, 6, 7. The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) (6) and SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) (7) trials, using liraglutide and semaglutide, respectively, demonstrated a significant reduction in major adverse cardiac events in high-risk cardiovascular (CV) disease patients with diabetes. The process of completing the sentence stems, receiving the profile report, dialogue at the workshop and subsequent coaching took me to a depth of reflection beyond that I have experienced from other interventions. The GLP workshop and related support has been, by far, the most valuable of these. To support future research, it_s important that laboratory staff and key stakeholders (both internal and possibly external) are able to easily find critical information when they need it.

Here is my blog ... ColonBroom nutrition